1,040,606 Shares of Corvus Pharmaceuticals, Inc. $CRVS Bought by Fisher Asset Management LLC

Fisher Asset Management LLC purchased a new stake in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS – Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 1,040,606 shares of the company’s stock, valued at approximately $11,988,000.

Other hedge funds have also added to or reduced their stakes in the company. Global Retirement Partners LLC bought a new stake in Corvus Pharmaceuticals during the 2nd quarter worth approximately $30,000. Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in shares of Corvus Pharmaceuticals in the second quarter valued at approximately $48,000. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Corvus Pharmaceuticals during the third quarter valued at approximately $50,000. State of Wyoming purchased a new position in shares of Corvus Pharmaceuticals during the second quarter valued at approximately $71,000. Finally, Meeder Asset Management Inc. purchased a new position in shares of Corvus Pharmaceuticals during the second quarter valued at approximately $90,000. Institutional investors and hedge funds own 46.64% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of Corvus Pharmaceuticals in a report on Wednesday, September 16th. Wall Street Zen cut Corvus Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday, November 7th. Mizuho set a $27.00 price objective on Corvus Pharmaceuticals in a research note on Thursday, October 29th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Corvus Pharmaceuticals in a report on Monday, October 26th. Finally, Ladenburg Thalmann & Co. Inc. raised shares of Corvus Pharmaceuticals to a “strong-buy” rating in a report on Thursday, July 30th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $32.83.

View Our Latest Report on Corvus Pharmaceuticals

Corvus Pharmaceuticals Price Performance

Corvus Pharmaceuticals stock opened at $10.64 on Monday. Corvus Pharmaceuticals, Inc. has a 52 week low of $6.39 and a 52 week high of $26.95. The company’s 50 day moving average price is $11.18 and its two-hundred day moving average price is $14.04. The stock has a market cap of $897.48 million, a P/E ratio of -14.99 and a beta of 1.57.

Corvus Pharmaceuticals (NASDAQ:CRVS – Get Free Report) last announced its earnings results on Thursday, November 5th. The company reported ($0.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.03). On average, equities analysts anticipate that Corvus Pharmaceuticals, Inc. will post -0.81 EPS for the current year.

Corvus Pharmaceuticals News Summary

Here’s some of the latest news about CRVS:

  • Positive Sentiment: A Globe and Mail headline includes Corvus among healthcare stocks analysts are bullish on, though the article details provided do not specify a rating or price target. Analysts Are Bullish on Top Healthcare Stocks: Corvus Pharmaceuticals (CRVS), Achieve Life Sciences (QUIT)
  • Negative Sentiment: HC Wainwright cut estimates across multiple periods. It now expects a $1.04-per-share loss in 2027, versus its prior $0.80 loss estimate, and a $0.90 loss in 2028, versus $0.37 previously. It also reduced its 2029 forecast from near breakeven to a $0.43 loss and lowered its 2030 profit estimate to $0.45 from $0.67. The revisions suggest a slower improvement in earnings and could weigh on investor sentiment. HC Wainwright earnings estimate updates

Insider Activity at Corvus Pharmaceuticals

In other Corvus Pharmaceuticals news, insider Jeffrey Arcara purchased 3,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 11th. The shares were acquired at an average cost of $11.46 per share, for a total transaction of $34,380.00. Following the completion of the acquisition, the insider owned 3,000 shares of the company’s stock, valued at $34,380. The trade was a ∞ increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders purchased 4,500 shares of company stock worth $50,478 over the last three months. Company insiders own 19.70% of the company’s stock.

Corvus Pharmaceuticals Company Profile

(Free Report)

Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing medicines that target the immune system to treat cancer and immune-related diseases. The company is based in Burlingame, California, and its work centers on therapies in clinical development rather than marketed products. Its lead candidate, soquelitinib (also known as CPI-818), is an oral inhibitor of interleukin-2-inducible T-cell kinase, or ITK. Corvus is developing the drug for T-cell lymphoma and has also explored its potential in inflammatory and autoimmune conditions, including atopic dermatitis.

Featured Articles

Want to see what other hedge funds are holding CRVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS – Free Report).

Institutional Ownership by Quarter for Corvus Pharmaceuticals (NASDAQ:CRVS)

Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.